Цирконий (⁸⁹Zr) гирентуксимаб сенведоксам

Rec. INN (наименование, зарегистрированное ВОЗ)

2768427-84-3

immunoglobulin G1-kappa, anti-[Homo sapiens carbonic anhydrase 9 (CA9, carbonic anhydrase IX, CAIX, MN, G250)], chimeric monoclonal antibody; conjugated on l-lysine residues to zirconium (⁸⁹Zr) radiolabelled senvedoxam, with an average ratio of 1 to 1.5;
H-gamma1 heavy chain chimeric (1-449) [VH (Mus musculus IGHV5-6-2*01 (94.9%) -(IGHD) -IGHJ4*01 (88.2%), CDR-IMGT [8.8.12] (26-33.51-58.97-108)) (1-119) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS (448-449)) (120-449)], (222-214')-disulfide with L-kappa light chain chimeric (1'-214') [V-KAPPA (Mus musculus IGKV6-13*01 (93.7%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide, produced in the mouse myeloma cell line P3x63Ag8.653, glycoform alfa; substituted at the N⁶ nitrogen atoms of an average of 1.5 lysine residues, among which 449, with 3,14,25-trihydroxy-2,10,13,21,24,32-hexaoxo-3,9,14,20,25,31-hexaazapentatriacontan-35-oyl (senvedoxam) groups and converted to (⁸⁹Zr) zirconium (4+) chelate complex salts

Поделиться этой страницей